Clinical Trial Detail

NCT ID NCT02715284
Title A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors (GARNET)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Tesaro, Inc.
Indications

endometrial cancer

lung non-small cell carcinoma

Advanced Solid Tumor

Therapies

Dostarlimab

Age Groups: adult senior

No variant requirements are available.